Garutti Mattia, Cucciniello Linda, Arpino Grazia, Fabi Alessandra, Livi Lorenzo, Munzone Elisabetta, Staropoli Nicoletta, Zamagni Claudio, Zambelli Alberto, Puglisi Fabio
CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy.
CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy; Department of Medicine, University of Udine, Udine, Italy.
Clin Breast Cancer. 2023 Oct;23(7):e458-e469. doi: 10.1016/j.clbc.2023.07.006. Epub 2023 Jul 26.
Breast cancer represents the most commonly diagnosed neoplasm worldwide and the HER2-positive subtype accounts for nearly 1 in 5 breast cancers. The majority of patients with breast cancer present with an early-stage disease upon diagnosis, which is thus susceptible to virtually curative treatment strategies. For a stage, I T1a/b N0 HER2-positive disease, upfront surgery followed by adjuvant therapy is the preferred approach. However, there is some uncertainty regarding the appropriate management of stage cT1c cN0, as both the neoadjuvant approach and upfront surgery have been proven to be feasible therapeutic options. The aim of this Delphi consensus was to define the best strategies for the treatment of early HER2-positive breast cancer. This work may help clinicians in the management of early HER2-positive breast cancer.
乳腺癌是全球最常被诊断出的肿瘤，HER2阳性亚型约占五分之一的乳腺癌病例。大多数乳腺癌患者在确诊时处于疾病早期阶段，因此几乎可以采用根治性治疗策略。对于I期T1a/b N0 HER2阳性疾病，先行手术然后进行辅助治疗是首选方法。然而，对于cT1c cN0期的适当管理存在一些不确定性，因为新辅助治疗方法和先行手术均已被证明是可行的治疗选择。本次德尔菲共识的目的是确定早期HER2阳性乳腺癌的最佳治疗策略。这项工作可能有助于临床医生管理早期HER2阳性乳腺癌。
